Login to Your Account



Is it Lilly? ImClone Stays Mum on Mystery Big Pharma Bidder

By Jennifer Boggs


Friday, October 3, 2008
With two blockbuster products set to lose patent protection in the next two to three years, Eli Lilly and Co. certainly seems like a firm that would be willing to pay $70 per share - about $6.1 billion - to acquire ImClone Systems Inc., though the big pharma firm has neither confirmed nor denied that it is the unnamed bidder that topped Bristol-Myers Squibb Co.'s offer earlier this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription